ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Larimar Therapeutics Inc

Larimar Therapeutics Inc (LRMR)

9.49
0.065
(0.69%)
At close: July 24 4:00PM
9.49
0.02
( 0.21% )
After Hours: 4:06PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
9.49
Bid
9.20
Ask
10.20
Volume
335,670
9.29 Day's Range 9.97
2.18 52 Week Range 13.68
Market Cap
Previous Close
9.425
Open
9.35
Last Trade Time
16:02:16
Financial Volume
$ 3,249,932
VWAP
9.6819
Average Volume (3m)
543,571
Shares Outstanding
63,802,017
Dividend Yield
-
PE Ratio
-1.71
Earnings Per Share (EPS)
-0.58
Revenue
-
Net Profit
-36.95M

About Larimar Therapeutics Inc

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion p... Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Larimar Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LRMR. The last closing price for Larimar Therapeutics was $9.43. Over the last year, Larimar Therapeutics shares have traded in a share price range of $ 2.18 to $ 13.68.

Larimar Therapeutics currently has 63,802,017 shares outstanding. The market capitalization of Larimar Therapeutics is $601.33 million. Larimar Therapeutics has a price to earnings ratio (PE ratio) of -1.71.

LRMR Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.8-7.7745383867810.2910.379.084103859.57362536CS
42.4935.5714285714711.26.85572539.18646648CS
122.6338.33819241986.8611.26.85435718.50156166CS
264.99110.8888888894.513.684.255801569.07088376CS
526.26193.8080495363.2313.682.183732247.87190778CS
156-0.42-4.238143289619.9115.25811.532331796.30269041CS
260-2.51-20.91666666671225.871.531916017.15727713CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PBMPsyence Biomedical Ltd
$ 0.9825
(151.02%)
24.49M
ASNSActelis Networks Inc
$ 1.68
(21.74%)
3.11M
VKTXViking Therapeutics Inc
$ 60.91
(20.83%)
1.27M
PROPPrairie Operating Company
$ 10.61
(15.20%)
498
ATXIAvenue Therapeutics Inc
$ 4.03
(13.20%)
106.9k
DUOFangDD Network Group Ltd
$ 0.4511
(-16.15%)
205.91k
NUZENuZee Inc
$ 2.81
(-16.12%)
1.97M
MXLMaxLinear Inc
$ 18.70
(-16.11%)
310.41k
SLNASelina Hospitality PLC
$ 0.0384
(-15.97%)
13.1M
OSTOstin Technology Group Company Ltd
$ 0.3701
(-15.89%)
695.19k
PBMPsyence Biomedical Ltd
$ 0.9825
(151.02%)
24.49M
SLNASelina Hospitality PLC
$ 0.0384
(-15.97%)
13.1M
NVDANVIDIA Corporation
$ 114.53
(0.25%)
11.12M
SQQQProShares UltraPro Short QQQ
$ 9.00
(-0.66%)
4.92M
INTCIntel Corporation
$ 31.75
(0.16%)
3.4M

LRMR Discussion

View Posts
tw0122 tw0122 2 weeks ago
LRMR above $9 momentarily
πŸ‘οΈ0
Monksdream Monksdream 3 months ago
LRMR under $10

πŸ‘οΈ0
Monksdream Monksdream 4 months ago
LRMR under $10
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
LRMR new 52 week high
πŸ‘οΈ0
Monksdream Monksdream 5 months ago
LRMR new 52=week high
πŸ‘οΈ0
AJ Freely AJ Freely 12 months ago
$LRMR - Announced that the FDA has cleared the Company’s four-week, placebo-controlled, Phase 2 dose exploration trial of CTI-1601
👆Up 8% Pre-Market/ Current Price $3,40
πŸ‘οΈ0
magacrew2020 magacrew2020 1 year ago
could probably get through approval on just 25 mg if they are going to approve reta
πŸ‘οΈ0
subslover subslover 2 years ago
The company said it received feedback from the FDA on information needed to resolve CTI-1601's current clinical hold, as well as a proposed change for a second phase. CTI-1601 is a treatment for Friedreich's ataxia.

Larimer plans to submit a complete response to CTI-1601's clinical hold in the third quarter.

Larimar is also proposing a phase two, four-week dose exploration study in Friedreich's ataxia patients. Friedreich's ataxia is a rare disease that causes progressive nervous system damage and movement problems, usually beginning during childhood.
πŸ‘οΈ0
JJJ54 JJJ54 2 years ago
I voted NO on the 2022 Annual Meeting Vote. I recommend you do the same.
πŸ‘οΈ0
DarkPool DarkPool 2 years ago
Interesting.
πŸ‘οΈ0
oxnous oxnous 3 years ago
Waking up . But volume should be higher.
πŸ‘οΈ0
DewDiligence DewDiligence 4 years ago
LRMR 2Q20 resultsβ€”6/30/20 cash=$113.7M:

https://www.globenewswire.com/news-release/2020/08/11/2076240/0/en/Larimar-Therapeutics-Reports-Second-Quarter-2020-Operating-and-Financial-Results.html

No CC.
πŸ‘οΈ0
casenumber casenumber 4 years ago
Large chunks are being gobbled
Whales are lurking around?
πŸ‘οΈ0
subslover subslover 4 years ago
The company they are merging with looks pretty darn impressive
https://chondrialtherapeutics.com/
πŸ‘οΈ0
casenumber casenumber 5 years ago
Volume!
πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $ZFGN Video Chart 12-26-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $ZFGN Video Chart 12-24-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
whytestocks whytestocks 5 years ago
News: $ZFGN Penny Stocks To Buy Or Sell Before The End Of 2019?

These Penny Stocks Moved Big But Can They Continue Higher Before Next Year? Over the course of the year, plenty of penny stocks have generated significant gains for investors. Even as the year comes to a close, there are some penny stocks that are gaining momentum. It is often said that inve...

Got this from ZFGN - Penny Stocks To Buy Or Sell Before The End Of 2019?
πŸ‘οΈ0
Fat Thor Fat Thor 5 years ago
Like I said at .67 cents
πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $ZFGN Video Chart 12-23-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
casenumber casenumber 5 years ago
Wow...guess they will satisfy the 1dollar minimum nasd requirement with out rs.....
This will be huge when ticker change and merger consummated next month!

Scrap the notice of delisting boys.....

82M cash and 30M OS....sounds fun!
πŸ‘οΈ0
ClayTrader ClayTrader 5 years ago
* * $ZFGN Video Chart 12-20-2019 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
casenumber casenumber 5 years ago
Over a buck soon when ticker change completed....
πŸ‘οΈ0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
exactly is great
πŸ‘οΈ0
Fat Thor Fat Thor 5 years ago
Probably 3-9 months away still - appears to be a massive over correction and tax loss selling on the merger news. Just a short target at the moment. They will run this in Q1 pre-split to get a much more favorable ratio IMO. Let's see what happens. Lots of cash on hand here at very low burn rate per Q.

The transaction is expected to close in the first half of 2020, subject to approvals by stockholders of each company and other customary closing conditions.
πŸ‘οΈ0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
R/Split coming per 8k today
πŸ‘οΈ0
Fat Thor Fat Thor 5 years ago
December discounts. With 85 million in cash, a merger, and priced at 67 cents there's no way this doesn't run soon. 35 million O/S.
πŸ‘οΈ0
casenumber casenumber 5 years ago
Ticker change coming...Shorts will get burn if they will not cover or do damage control.
ZFGN has 82M dollars in cash!

The proposed merger will result in a combined publicly traded, clinical-stage biopharmaceutical company operating under a new name, Larimar Therapeutics, Inc.
πŸ‘οΈ0
casenumber casenumber 5 years ago
Shorts covering.. they have to before it gets out of control once the merger is official...
πŸ‘οΈ0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
10 day MA live chart huge oversold,safe here now,will recover nice
πŸ‘οΈ0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
bought 3k at 6391
πŸ‘οΈ0
Fat Thor Fat Thor 5 years ago
Just saw a bunch come through on tape that were vastly different but didn't indicate "out of sequence"...they were either out of sequence or it was a messed up market order. Just odd. This one is clearly under short attack. Volume could squeeze it near term.
πŸ‘οΈ0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
ZFGN~~Balance Sheet
Total Cash (mrq) 82.01M
Total Cash Per Share (mrq) 2.19
Total Debt (mrq) 24.35M
Total Debt/Equity (mrq) 40.67
Current Ratio (mrq) 5.11
Book Value Per Share (mrq) 1.60
https://finance.yahoo.com/quote/ZFGN/key-statistics?p=ZFGN



πŸ‘οΈ0
alchemytrader alchemytrader 5 years ago
not really. that would mean its been up and down, up and down. this is nothing but down..
πŸ‘οΈ0
Fat Thor Fat Thor 5 years ago
...this price action is ALL over the place. Crazy.
πŸ‘οΈ0
alchemytrader alchemytrader 5 years ago
man i hope so. just want out even now
πŸ‘οΈ0
BoilerRoom BoilerRoom 5 years ago
$ZFGN in at .70
πŸ‘οΈ0
BoilerRoom BoilerRoom 5 years ago
Short this
πŸ‘οΈ0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
will recover but sucks,waste of time
πŸ‘οΈ0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
Zafgen and Chondrial Therapeutics will host an investor conference call today, December 18, 2019, at 8:30 a.m.,
πŸ‘οΈ0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
Conference Call Information
Zafgen and Chondrial Therapeutics will host an investor conference call today, December 18, 2019, at 8:30 a.m., Eastern Time, to discuss the merger as well as other forward-looking information. Investors and other interested parties may participate by dialing (844) 824-7428 in the United States or (973) 500-2177 outside the United States and referencing conference ID number 5688136. The call will also be webcast live on the Company's website at https://zafgen.gcs-web.com/events-and-presentations. A replay of this conference call will be available beginning at 11:30 a.m. ET on December 18, 2019 through December 25, 2019 by dialing (855) 859-2056 in the United States or (404) 537-3406 outside the United States. To access the replay please provide Conference ID number 5688136.
πŸ‘οΈ0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
dont think so
πŸ‘οΈ0
Widowsson32 Widowsson32 5 years ago
This is done no benefit to this company but ONTX will make you very rich
πŸ‘οΈ0
alchemytrader alchemytrader 5 years ago
institutions selling off?
πŸ‘οΈ0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
the news is great,why?
πŸ‘οΈ0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
fffffffffffffffffff MMS
πŸ‘οΈ0
alchemytrader alchemytrader 5 years ago
i guess were screwed
πŸ‘οΈ0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
f MMs
πŸ‘οΈ0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
.79 f
πŸ‘οΈ0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
what the heck is going on here?
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock